18 June 2013
Keywords: roche, fuzeon, cost-effective, hiv, new, evaluation, presented
Article | 03 November 2003
A new evaluation presented at the European AIDS Clinical SocietyCongress in Warsaw, Poland, at end-October shows that Fuzeon
(enfuvirtide) was ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 November 2003
© 2013 thepharmaletter.com